These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31446882)

  • 1. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    Tumori; 2019 Dec; 105(6):465-473. PubMed ID: 31446882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
    Davis EJ; Perez MC; Ayoubi N; Zhao S; Ye F; Wang DY; Sosman JA; Al-Rohil RN; Eroglu Z; Johnson DB
    J Immunother; 2019; 42(6):221-227. PubMed ID: 30882548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
    Xu J; Zhao J; Wang J; Sun C; Zhu X
    Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender C; Enk A; Gutzmer R; Hassel JC
    Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
    Mallardo D; Fordellone M; White A; Vowinckel J; Bailey M; Sparano F; Sorrentino A; Mallardo M; Facchini BA; De Filippi R; Ferrara G; Vanella V; Beeler K; Chiodini P; Cesano A; Warren S; Ascierto PA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
    Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
    Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
    Betof AS; Nipp RD; Giobbie-Hurder A; Johnpulle RAN; Rubin K; Rubinstein SM; Flaherty KT; Lawrence DP; Johnson DB; Sullivan RJ
    Oncologist; 2017 Aug; 22(8):963-971. PubMed ID: 28476944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
    Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
    Front Immunol; 2021; 12():691032. PubMed ID: 34290710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody.
    Lee J; Lee SJ; Kim K; Kim ST; Jang KT; Lee J
    BMC Cancer; 2019 Aug; 19(1):805. PubMed ID: 31412814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.